Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Author's Avatar
Feb 01, 2023
  • SON-1210 elicited no serious adverse events in repeat, subcutaneous dosing in a GLP toxicology study
  • SON-1210 was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose level
  • Data show controlled induction of IFNg with no signs of cytokine release syndrome or off-target toxicity